Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15623705.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.
Medical subject headings
- Autoantibodies
- Immunoglobulin G
- Immunoglobulin M
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Myelin-Associated Glycoprotein
- Protein Processing, Post-Translational